CanariaBio has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its investigational drug product, MAb-AR20.5, targeting pancreatic cancer.
US-based clinical stage biotechnology company Abcuro has raised $155m from Series B financing round to further progress autoimmune pipeline.
Day One Biopharmaceuticals has signed a global license agreement and research partnership with Sprint Bioscience to advance Vaccinia-related kinase 1 (VRK1) programme.
Genprex has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its lead drug candidate, REQORSA Immunogene Therapy (quratusugene ozeplasmid), to treat small cell lung cancer (SCLC).
Bristol Myers Squibb has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) which recommended approval on Opdivo (nivolumab) for use as an adjuvant treatment in patients with completely resected stage IIB or IIC melanoma.
The Janssen Pharmaceutical Companies of Johnson & Johnson is seeking approval of a new indication for Carvykti (ciltacabtagene autoleucel; cilta-cel) from the US Food and Drug Administration (FDA) through submission of a supplemental Biologics License Application (sBLA).
The US Food and Drug Administration has granted approval to Gamida Cell for Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy.
Caris Life Sciences and Flare Therapeutics have announced a partnership to advance the precision oncology pipeline of the latter into clinical trials.
Marmara Research Center (MAM) and The Scientific and Technological Research Council of Türkiye (TÜBITAK) have commenced Medical Biotechnology Research Center (MEDIBIYO) for the production of drugs and vaccines on a pilot scale, reported Daily Sabah.
UK-based oncology therapeutics company Mosaic Therapeutics has raised $28m from series A funding round.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.